Rybelsus Post-Bariatric Surgery Use: What Clinicians and Patients Need to Know

What does the Rybelsus label cover?

The Rybelsus and Ozempic tablet label is written for adults with type 2 diabetes. It is indicated as an adjunct to diet and exercise to improve glycemic control, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for them [1]. It is not a weight-loss label [1].

The dosing section gives one schedule: 3 mg once daily for days 1 to 30, 7 mg for days 31 to 60, then 7 mg or 14 mg from day 61 depending on how much additional glycemic control is needed [1]. The 3 mg starting dose is explicitly not effective for glycemic control [1]. Rybelsus and Ozempic tablets are not substitutable on a milligram-for-milligram basis, and the label has separate instructions for switching from Ozempic injections to the tablets [1].

How the tablet is absorbed

Most small-molecule drugs are absorbed in the intestine. Oral semaglutide is different. In the studies describing how the tablet works, absorption took place in the stomach, was confined to an area close to the tablet surface, and required co-formulation with SNAC; SNAC protects the peptide from enzymatic breakdown by buffering locally and only transiently enhances absorption [2].

Two common operations change the stomach in different ways. Sleeve gastrectomy speeds up emptying. In a prospective study of 14 patients who had a sleeve, the gastric emptying half-time for solids in the 9 patients with preoperative measurements fell from 86.5 minutes before surgery to 62.5 minutes at 6 months and 60.8 minutes at 24 months (P<0.05) [4]. Gastric bypass reshapes the stomach differently.

What the post-bariatric GLP-1 evidence actually tested

The randomized trial in this space used liraglutide, a daily injected GLP-1 agonist, not oral semaglutide. GRAVITAS randomized 80 adults with persistent or recurrent type 2 diabetes at least a year after gastric bypass or sleeve gastrectomy to liraglutide 1.8 mg daily (53 people) or placebo (27) for 26 weeks. HbA1c fell by 13.3 mmol/mol, about 1.22 percentage points, more on liraglutide than placebo (95% CI 7.0 to 19.7 mmol/mol; P=0.0001), and type of surgery did not significantly change the result [3]. Adverse effects, mostly gastrointestinal, were reported by 45% of those on liraglutide and 41% on placebo [3].

For oral semaglutide itself, PIONEER 4 compared oral semaglutide escalated to 14 mg, subcutaneous liraglutide 1.8 mg, and placebo in 711 adults with type 2 diabetes on metformin for 52 weeks, with HbA1c change at week 26 as the primary endpoint [5].

The cardiovascular evidence behind the tablet's label comes from SOUL: 9,650 adults aged 50 or older with type 2 diabetes plus atherosclerotic cardiovascular disease, chronic kidney disease, or both, taking oral semaglutide up to 14 mg or placebo for a median of 49.5 months. Major adverse cardiovascular events occurred in 12.0% versus 13.8% (HR 0.86, 95% CI 0.77 to 0.96) [6]. PIONEER 6, with 3,183 high-risk adults and a median 15.9 months, established noninferiority to placebo for the same composite (3.8% versus 4.8%; HR 0.79, 95% CI 0.57 to 1.11) [7].

What the label says about taking it

The label instructs patients to take the tablet once daily in the morning on an empty stomach with up to 4 ounces of plain water, swallow it whole, and wait at least 30 minutes before food, other drinks, or other oral medicines [1].

The label notes that semaglutide delays gastric emptying and can affect absorption of other oral drugs, and says to consider increased clinical or laboratory monitoring with oral drugs that have a narrow therapeutic index. Levothyroxine exposure rose 33% (90% CI 1.25 to 1.42) when given with semaglutide tablets [1].

Gastrointestinal tolerability in the tablet trials was dose-related. In the pooled placebo-controlled trials, any GI adverse reaction occurred in 41% on 14 mg, 32% on 7 mg and 21% on placebo, with nausea in 20%, 11% and 6% respectively. Severe GI reactions occurred in 2.0%, 0.6% and 0.3%, and 8% on 14 mg stopped treatment for GI reasons versus 1% on placebo [1]. The label says the drug is not recommended in patients with severe gastroparesis; it does not state that semaglutide causes gastroparesis [1].

The rest of the label applies regardless of surgical history. The boxed warning covers thyroid C-cell tumors in rodents, with a contraindication for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, and lists neck mass, trouble swallowing, shortness of breath and persistent hoarseness as symptoms; routine calcitonin monitoring or thyroid ultrasound is of uncertain value [1]. Other warnings cover acute pancreatitis, acute gallbladder disease, kidney injury from volume depletion, pulmonary aspiration during general anesthesia or deep sedation, and hypoglycemia when combined with insulin or a sulfonylurea [1].

Weight regain after bariatric surgery

A systematic review found that weight regain has been observed in a subset of patients after bariatric surgery, varies by operation and length of follow-up, and has multiple overlapping patient-specific and operation-specific causes [8]. The Rybelsus label does not include a weight-loss indication [1].

What is not known

The closest randomized evidence in this population is GRAVITAS, which tested injected liraglutide, not oral semaglutide: HbA1c improved more with liraglutide than placebo over 26 weeks [3]. We found no study that measured how bariatric surgery affects semaglutide blood levels from the tablet.